FGP
VRTX icon

Freestone Grove Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Freestone Grove Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-110,283
Closed -$43.2M – 965
2025
Q3 		$43.2M Buy
+110,283
New +$46.1M 0.32% 110

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Freestone Grove Partners's VRTX Position: Q4 2025 in Review

Freestone Grove Partners sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 110,283 shares — an estimated $43.2M sold.

Freestone Grove Partners first reported a position in VRTX in Q3 2025 and held it in 1 quarter. The position peaked at $43.2M in Q3 2025. 1,670 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • Freestone Grove Partners reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Freestone Grove Partners sold 110,283 Vertex Pharmaceuticals shares in Q4 2025, an estimated $43.2M.
  • Freestone Grove Partners first reported a position in Vertex Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Freestone Grove Partners's Vertex Pharmaceuticals position peaked at $43.2M in Q3 2025.
  • 1,670 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Freestone Grove Partners's 13F filing for Q4 2025, filed 17 Feb 2026.